SK44299A3 - Colonic delivery of weak acid drugs - Google Patents

Colonic delivery of weak acid drugs Download PDF

Info

Publication number: SK44299A3
Authority: SK; Slovakia
Prior art keywords: composition; drug; salt; ridogrel; composition according
Prior art date: 1996-10-04

Application number

SK442-99A

Other languages

English (en)

Slovak (sk)

Inventor

Peter James Watts

Original Assignee

West Pharm Serv Drug Res Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-10-04

Filing date

1997-10-06

Publication date

2000-05-16

1997-10-06 Application filed by West Pharm Serv Drug Res Ltd filed Critical West Pharm Serv Drug Res Ltd

2000-05-16 Publication of SK44299A3 publication Critical patent/SK44299A3/sk

Links

239000003814 drug Substances 0.000 title claims abstract description 73
229940079593 drug Drugs 0.000 title claims abstract description 60
239000002253 acid Substances 0.000 title claims abstract description 14
230000000112 colonic effect Effects 0.000 title description 2
239000000203 mixture Substances 0.000 claims abstract description 72
150000003839 salts Chemical class 0.000 claims abstract description 22
239000012528 membrane Substances 0.000 claims abstract description 16
238000013270 controlled release Methods 0.000 claims abstract description 14
-1 alkali metal salt Chemical class 0.000 claims abstract description 11
229910052783 alkali metal Inorganic materials 0.000 claims abstract description 9
229950006674 ridogrel Drugs 0.000 claims description 67
GLLPUTYLZIKEGF-HAVVHWLPSA-N ridogrel Chemical group C=1C=CC(C(F)(F)F)=CC=1C(=N/OCCCCC(=O)O)\C1=CC=CN=C1 GLLPUTYLZIKEGF-HAVVHWLPSA-N 0.000 claims description 66
239000006187 pill Substances 0.000 claims description 44
210000001072 colon Anatomy 0.000 claims description 27
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 26
238000000576 coating method Methods 0.000 claims description 26
239000011248 coating agent Substances 0.000 claims description 25
239000002775 capsule Substances 0.000 claims description 22
239000011734 sodium Substances 0.000 claims description 19
229910052708 sodium Inorganic materials 0.000 claims description 19
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 18
238000000034 method Methods 0.000 claims description 16
239000001856 Ethyl cellulose Substances 0.000 claims description 13
235000019325 ethyl cellulose Nutrition 0.000 claims description 13
229920001249 ethyl cellulose Polymers 0.000 claims description 13
239000000126 substance Substances 0.000 claims description 10
229920002472 Starch Polymers 0.000 claims description 8
235000019698 starch Nutrition 0.000 claims description 8
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 7
208000011231 Crohn disease Diseases 0.000 claims description 6
208000025865 Ulcer Diseases 0.000 claims description 6
210000003405 ileum Anatomy 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
239000008107 starch Substances 0.000 claims description 6
206010061218 Inflammation Diseases 0.000 claims description 5
230000004054 inflammatory process Effects 0.000 claims description 5
208000002551 irritable bowel syndrome Diseases 0.000 claims description 5
238000009792 diffusion process Methods 0.000 claims description 4
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 3
239000011324 bead Substances 0.000 claims description 3
239000003112 inhibitor Substances 0.000 claims description 3
229920000193 polymethacrylate Polymers 0.000 claims description 3
108010076197 prostaglandin endoperoxide receptor Proteins 0.000 claims description 3
239000002464 receptor antagonist Substances 0.000 claims description 3
229940044551 receptor antagonist Drugs 0.000 claims description 3
238000013268 sustained release Methods 0.000 claims description 3
239000012730 sustained-release form Substances 0.000 claims description 3
RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 claims description 3
229920003163 Eudragit® NE 30 D Polymers 0.000 claims description 2
108090000300 Thromboxane Receptors Proteins 0.000 claims description 2
DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 claims description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
150000001340 alkali metals Chemical class 0.000 claims 1
230000001747 exhibiting effect Effects 0.000 claims 1
229910052700 potassium Inorganic materials 0.000 claims 1
239000011591 potassium Substances 0.000 claims 1
238000009472 formulation Methods 0.000 abstract description 11
150000001875 compounds Chemical class 0.000 abstract description 4
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 18
229920000036 polyvinylpyrrolidone Polymers 0.000 description 18
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 18
229940069328 povidone Drugs 0.000 description 18
229920000642 polymer Polymers 0.000 description 17
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 15
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 15
230000000968 intestinal effect Effects 0.000 description 15
239000010410 layer Substances 0.000 description 14
238000004090 dissolution Methods 0.000 description 11
238000002360 preparation method Methods 0.000 description 11
239000003826 tablet Substances 0.000 description 11
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 9
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
229920003134 Eudragit® polymer Polymers 0.000 description 7
210000001035 gastrointestinal tract Anatomy 0.000 description 7
239000008188 pellet Substances 0.000 description 7
229920003139 Eudragit® L 100 Polymers 0.000 description 6
210000000936 intestine Anatomy 0.000 description 6
230000002378 acidificating effect Effects 0.000 description 5
210000000813 small intestine Anatomy 0.000 description 5
239000000454 talc Substances 0.000 description 5
229910052623 talc Inorganic materials 0.000 description 5
229920000856 Amylose Polymers 0.000 description 4
229920003161 Eudragit® RS 30 D Polymers 0.000 description 4
229920003152 Eudragit® RS polymer Polymers 0.000 description 4
229920003141 Eudragit® S 100 Polymers 0.000 description 4
239000008199 coating composition Substances 0.000 description 4
239000006185 dispersion Substances 0.000 description 4
FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 4
238000004806 packaging method and process Methods 0.000 description 4
230000036470 plasma concentration Effects 0.000 description 4
239000004014 plasticizer Substances 0.000 description 4
159000000000 sodium salts Chemical class 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
229920003091 Methocel™ Polymers 0.000 description 3
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 3
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 3
239000008186 active pharmaceutical agent Substances 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
229940088679 drug related substance Drugs 0.000 description 3
150000004676 glycans Chemical class 0.000 description 3
239000000017 hydrogel Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 3
125000005395 methacrylic acid group Chemical group 0.000 description 3
JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
229920001282 polysaccharide Polymers 0.000 description 3
239000005017 polysaccharide Substances 0.000 description 3
230000009467 reduction Effects 0.000 description 3
239000007921 spray Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
239000000725 suspension Substances 0.000 description 3
239000001069 triethyl citrate Substances 0.000 description 3
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 3
235000013769 triethyl citrate Nutrition 0.000 description 3
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
229920001287 Chondroitin sulfate Polymers 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
229920003155 Eudragit® RL 100 Polymers 0.000 description 2
229920003159 Eudragit® RS 100 Polymers 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
229920002907 Guar gum Polymers 0.000 description 2
101000607872 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 21 Proteins 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
229920003081 Povidone K 30 Polymers 0.000 description 2
229920000294 Resistant starch Polymers 0.000 description 2
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
102100039918 Ubiquitin carboxyl-terminal hydrolase 21 Human genes 0.000 description 2
230000009471 action Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000007963 capsule composition Substances 0.000 description 2
229940081734 cellulose acetate phthalate Drugs 0.000 description 2
229940059329 chondroitin sulfate Drugs 0.000 description 2
229920001688 coating polymer Polymers 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
238000009826 distribution Methods 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000001125 extrusion Methods 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000000665 guar gum Substances 0.000 description 2
235000010417 guar gum Nutrition 0.000 description 2
229960002154 guar gum Drugs 0.000 description 2
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
210000002429 large intestine Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229920003145 methacrylic acid copolymer Polymers 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
229920001542 oligosaccharide Polymers 0.000 description 2
150000002482 oligosaccharides Chemical class 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
229920001277 pectin Polymers 0.000 description 2
239000001814 pectin Substances 0.000 description 2
235000010987 pectin Nutrition 0.000 description 2
229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
229940100467 polyvinyl acetate phthalate Drugs 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
235000021254 resistant starch Nutrition 0.000 description 2
238000005563 spheronization Methods 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical compound OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
241000819038 Chichester Species 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
239000001116 FEMA 4028 Substances 0.000 description 1
229920002683 Glycosaminoglycan Polymers 0.000 description 1
WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical class CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010023799 Large intestinal ulcer Diseases 0.000 description 1
MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
238000005299 abrasion Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
210000001815 ascending colon Anatomy 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
235000011175 beta-cyclodextrine Nutrition 0.000 description 1
229960004853 betadex Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
AWKDEEXFAVIGAF-UHFFFAOYSA-N bis(4-ethenylphenyl)diazene Chemical compound C1=CC(C=C)=CC=C1N=NC1=CC=C(C=C)C=C1 AWKDEEXFAVIGAF-UHFFFAOYSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
238000007664 blowing Methods 0.000 description 1
229910021538 borax Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
WZNRVWBKYDHTKI-UHFFFAOYSA-N cellulose, acetate 1,2,4-benzenetricarboxylate Chemical compound OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.OC(=O)C1=CC(C(=O)O)=CC=C1C(=O)OCC1C(OC2C(C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(COC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)O2)OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)O1 WZNRVWBKYDHTKI-UHFFFAOYSA-N 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
239000011247 coating layer Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000013267 controlled drug release Methods 0.000 description 1
229960000265 cromoglicic acid Drugs 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
239000012055 enteric layer Substances 0.000 description 1
239000002360 explosive Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
238000007429 general method Methods 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
229940055742 indium-111 Drugs 0.000 description 1
APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
230000003993 interaction Effects 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
229960000511 lactulose Drugs 0.000 description 1
PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
244000005706 microflora Species 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000003607 modifier Substances 0.000 description 1
239000004570 mortar (masonry) Substances 0.000 description 1
229920005615 natural polymer Polymers 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000005304 optical glass Substances 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
229920002744 polyvinyl acetate phthalate Polymers 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000000541 pulsatile effect Effects 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000010526 radical polymerization reaction Methods 0.000 description 1
MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
229920005604 random copolymer Polymers 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
239000004208 shellac Substances 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
239000004328 sodium tetraborate Substances 0.000 description 1
235000010339 sodium tetraborate Nutrition 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
125000005591 trimellitate group Chemical group 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
230000036269 ulceration Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK442-99A 1996-10-04 1997-10-06 Colonic delivery of weak acid drugs SK44299A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9620709.7A GB9620709D0 (en)	1996-10-04	1996-10-04	Colonic delivery of weak acid drugs
PCT/GB1997/002726 WO1998015265A1 (en)	1996-10-04	1997-10-06	Colonic delivery of weak acid drugs

Publications (1)

Publication Number	Publication Date
SK44299A3 true SK44299A3 (en)	2000-05-16

Family

ID=10800944

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK442-99A SK44299A3 (en)	1996-10-04	1997-10-06	Colonic delivery of weak acid drugs

Country Status (17)

Country	Link
US (1)	US20020015729A1 (cs)
EP (1)	EP0956006A1 (cs)
JP (1)	JP2001501642A (cs)
KR (1)	KR20000048939A (cs)
CN (1)	CN1232386A (cs)
AU (1)	AU732210B2 (cs)
BR (1)	BR9712163A (cs)
CA (1)	CA2264637A1 (cs)
CZ (1)	CZ118899A3 (cs)
GB (2)	GB9620709D0 (cs)
HU (1)	HUP9904320A3 (cs)
IL (1)	IL129185A0 (cs)
NO (1)	NO991519L (cs)
NZ (1)	NZ334313A (cs)
PL (1)	PL332555A1 (cs)
SK (1)	SK44299A3 (cs)
WO (1)	WO1998015265A1 (cs)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE476968T1 (de)	2000-09-06	2010-08-15	Mitsubishi Tanabe Pharma Corp	Granulat-zubereitungen zur oralen verabreichung
US20030175349A1 (en) *	2001-01-30	2003-09-18	Council Of Scientific And Industrial Research	Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
GB0203421D0 (en) *	2002-02-13	2002-04-03	Alizyme Therapeutics Ltd	Composition
MY148805A (en) *	2002-10-16	2013-05-31	Takeda Pharmaceutical	Controlled release preparation
MXPA05010636A (es) *	2003-04-04	2005-12-12	Pharmacia Corp	Comprimidos de multiparticulas preparados por compresion de liberacion oral prolongada.
FR3008281B1 (fr) *	2013-07-15	2015-07-31	Chantelle	Coque de soutien-gorge et son procede de fabrication
JP2021528483A (ja) *	2018-05-03	2021-10-21	エムダブリュエンキャップリミテッド	下部胃腸管への医薬の送達のための剤形

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4211777A (en) *	1977-11-25	1980-07-08	Fisons Limited	Compositions comprising a compound having sodium cromoglycate activity and aminosalicylic acid
ZA825384B (en) *	1981-07-31	1983-05-25	Tillott J B Ltd	Orally administrable pharmaceutical compositions
US4746671A (en) *	1985-11-04	1988-05-24	Janssen Pharmaceutica N.V.	Pharmaceutical use of [[[(3-pyridinyl)methylen]amino]oxy]alkanoic acids and esters
SE8803822D0 (sv) *	1988-10-26	1988-10-26		Novel dosage form
GB2253346A (en) *	1991-02-22	1992-09-09	John Rhodes	Delayed release oral dosage forms for treatment of intestinal disorders
DE69117955T2 (de) *	1990-07-20	1996-09-19	Tillotts Pharma Ag, Ziefen	Produkte und verfahren zur behandlung des verdauungskanals
EP0520119A1 (de) *	1991-06-17	1992-12-30	Spirig Ag Pharmazeutische Präparate	Neue orale Diclofenaczubereitung
HU227530B1 (en) *	1991-11-22	2011-07-28	Warner Chilcott Company	Delayed-release compositions containing risedronate and process for their production
IT1260505B (it) *	1992-06-01	1996-04-09	Poli Ind Chimica Spa	Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
US5376384A (en) *	1992-12-23	1994-12-27	Kinaform Technology, Inc.	Delayed, sustained-release pharmaceutical preparation
JP2916978B2 (ja) *	1993-08-25	1999-07-05	エスエス製薬株式会社	放出開始制御型製剤
GB9412394D0 (en) *	1994-06-21	1994-08-10	Danbiosyst Uk	Colonic drug delivery composition
AU5397496A (en) *	1995-03-28	1996-10-16	Janssen Pharmaceutica N.V.	Low dose ridogrel formulations and their use for the treatme nt of inflammatory bowel diseases

1996
- 1996-10-04 GB GBGB9620709.7A patent/GB9620709D0/en active Pending
1997
- 1997-10-06 KR KR1019990702977A patent/KR20000048939A/ko not_active Withdrawn
- 1997-10-06 CA CA002264637A patent/CA2264637A1/en not_active Abandoned
- 1997-10-06 IL IL12918597A patent/IL129185A0/xx unknown
- 1997-10-06 GB GB9907298A patent/GB2333042B/en not_active Expired - Fee Related
- 1997-10-06 EP EP97944010A patent/EP0956006A1/en not_active Withdrawn
- 1997-10-06 BR BR9712163-0A patent/BR9712163A/pt not_active Application Discontinuation
- 1997-10-06 NZ NZ334313A patent/NZ334313A/xx unknown
- 1997-10-06 WO PCT/GB1997/002726 patent/WO1998015265A1/en not_active Ceased
- 1997-10-06 AU AU45655/97A patent/AU732210B2/en not_active Ceased
- 1997-10-06 CN CN97198515A patent/CN1232386A/zh active Pending
- 1997-10-06 PL PL97332555A patent/PL332555A1/xx unknown
- 1997-10-06 SK SK442-99A patent/SK44299A3/sk unknown
- 1997-10-06 HU HU9904320A patent/HUP9904320A3/hu unknown
- 1997-10-06 CZ CZ991188A patent/CZ118899A3/cs unknown
- 1997-10-06 JP JP10517294A patent/JP2001501642A/ja not_active Ceased
- 1997-10-06 US US09/269,903 patent/US20020015729A1/en not_active Abandoned
1999
- 1999-03-29 NO NO991519A patent/NO991519L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP0956006A1 (en)	1999-11-17
IL129185A0 (en)	2000-02-17
NO991519D0 (no)	1999-03-29
AU4565597A (en)	1998-05-05
PL332555A1 (en)	1999-09-13
GB9620709D0 (en)	1996-11-20
BR9712163A (pt)	2000-01-18
US20020015729A1 (en)	2002-02-07
CN1232386A (zh)	1999-10-20
WO1998015265A1 (en)	1998-04-16
GB2333042A (en)	1999-07-14
CA2264637A1 (en)	1998-04-16
HUP9904320A2 (hu)	2000-06-28
NZ334313A (en)	2000-09-29
CZ118899A3 (cs)	1999-07-14
AU732210B2 (en)	2001-04-12
KR20000048939A (ko)	2000-07-25
NO991519L (no)	1999-03-29
HUP9904320A3 (en)	2000-08-28
GB9907298D0 (en)	1999-05-26
JP2001501642A (ja)	2001-02-06
GB2333042B (en)	2000-10-18

Publication	Publication Date	Title
JP5808670B2 (ja)	2015-11-10	弱塩基性薬物を含む組成物及び徐放性剤形
CA2337046C (en)	2005-08-16	Sustained release pharmaceutical preparation
JP2002525314A (ja)	2002-08-13	Ｈｐｍｃカプセルを使用する腸及び結腸への送達
SK285152B6 (sk)	2006-07-07	Enterický potiahnutý farmaceutický prostriedok a spôsob jeho prípravy
CZ300497B6 (cs)	2009-06-03	Farmaceutický prostredek, jeho sferonizované jádro a zpusob prípravy jader a farmaceutického prostredku
EP1622601B1 (en)	2009-02-11	Pharmaceutical compositions
US20020031550A1 (en)	2002-03-14	Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3yl) acetonitrile monohydrochloride
AU724086B2 (en)	2000-09-14	Controlled release dosage form of (R-(Z))-alpha- (methoxyimino)-alpha-(1-azabicyclo(2.2.2)oct-3-yl) acetonitrile monohydrochloride
CA2304135C (en)	2009-01-06	Medicament formulation with a controlled release of an active agent
JP4771956B2 (ja)	2011-09-14	バイオアベイラビリティーエンハンサを含む第四級アンモニウム化合物の組成物
SK44299A3 (en)	2000-05-16	Colonic delivery of weak acid drugs
US20230181479A1 (en)	2023-06-15	Polymer based formulation for release of drugs and bioactives at specific git sites
AU627335B2 (en)	1992-08-20	Aspirin granules with gastroprotectant coating
MXPA99003093A (en)	2000-05-01	Colonic delivery of weak acid drugs
MXPA06004018A (es)	2006-10-17	Composiciones de amonio cuaternario que contienen mejoradores de biodisponibilidad